All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Visual abstract | Eprenetapopt plus azacitidine as a post-allo-HCT treatment for patients with TP53-mutated AML and MDS: Results from a phase II trial

Sep 15, 2022
Learning objective: After reading this visual abstract, learners will be able to cite a new development in the treatment of AML/MDS.

Bookmark this article

The AML Hub is pleased to present a visual abstract representing key data from a phase II trial (NCT03931291) evaluating eprenetapopt plus azacitidine as a post-allogeneic hematopoietic stem cell transplantation treatment for patients with TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.


Visual Abstract

To download this visual abstract, click below.

Download here


Subscribe to get the best content related to AML delivered to your inbox